Welcome to our dedicated page for OmniAb news (Ticker: OABI), a resource for investors and traders seeking the latest updates and insights on OmniAb stock.
OmniAb, Inc. (OABI) delivers cutting-edge therapeutic antibody discovery through proprietary transgenic animal platforms and high-throughput screening technologies. This page provides investors and industry professionals with essential updates on the company's scientific advancements, financial performance, and strategic collaborations.
Access consolidated news about OmniAb's drug discovery milestones, including FDA designations, partnership announcements with pharmaceutical leaders, and technology licensing developments. Our repository tracks critical updates ranging from preclinical breakthroughs to quarterly earnings reports.
Key content includes analyses of OmniRat® platform innovations, progress in antibody therapeutic pipelines, and financial disclosures. Bookmark this page to efficiently monitor how OABI's antibody generation capabilities influence biopharmaceutical development timelines and partner-driven revenue streams.
OmniAb, Inc. (NASDAQ: OABI) announced its participation in five investor conferences throughout May 2023. Highlights include:
- H.C. Wainwright BioConnect Investor Conference on May 2, 2023, featuring a fireside chat at 9:30 a.m. ET and one-on-one meetings in New York City.
- E.F. Hutton Global Conference on May 10-11, 2023, with one-on-one meetings on May 11 at The Plaza Hotel, New York City.
- Benchmark 3rd Annual Virtual Healthcare House Call on May 23, 2023, hosting virtual one-on-one meetings.
- B. Riley Securities 23rd Annual Institutional Investor Conference on May 24-25, 2023, with meetings on May 24 in Beverly Hills.
- Craig-Hallum 20th Annual Institutional Investor Conference on May 31, 2023, at The Depot Renaissance Minneapolis Hotel.
OmniAb's platform supports pharmaceutical partners in discovering next-generation therapeutics via diverse antibody repertoires.
OmniAb, Inc. (NASDAQ: OABI) reported strong financial results for Q4 and full-year 2022, with Q4 revenue of $35.3 million, up from $15.3 million in Q4 2021, driven by a $25 million milestone from TECVAYLI™ sales. Full-year revenue reached $59.1 million, an increase from $34.7 million in 2021. Despite net losses of $22.3 million for 2022, improved from a loss of $27 million in 2021, the company ended the year with $88.3 million in cash. OmniAb also signed 13 new partnerships and has 69 active partners pursuing 291 programs. The company anticipates recognizing $10 million more in milestone payments in 2023, showcasing a robust pipeline and growth potential.
OmniAb, Inc. (NASDAQ: OABI) will release its financial results for the three and 12 months ending
FAQ
What is the current stock price of OmniAb (OABI)?
What is the market cap of OmniAb (OABI)?
